The functional balance of metalloproteinases and inhibitors in tissue degradation: Relevance to oral pathologies

Journal of the Royal College of Surgeons of Edinburgh

Volumn 42, Issue 3, 1997, Pages 154-160

  Reynolds, J J ^a,b   Meikle, M C ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Collagenase; Metalloproteinase; Periodontal disease; TIMP; Tissue degradation

Indexed keywords

COLLAGEN; COLLAGEN TYPE 4; COLLAGENASE; GELATINASE; GLYCOPROTEIN; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PROTEOGLYCAN; STROMELYSIN;

EXTRACELLULAR MATRIX; HUMAN; PERIODONTAL DISEASE; REVIEW; TISSUE DEGENERATION;

BIOCHEMISTRY; CLONING, MOLECULAR; COLLAGEN; COLLAGENASES; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; METALLOENDOPEPTIDASES; MOUTH DISEASES; MOUTH MUCOSA; PERIODONTAL DISEASES; PROTEASE INHIBITORS; PROTEOGLYCANS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 0030960453     PISSN: 00358835     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Birkedal-Hansen H, Moore WGI, Bodden MK et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
2. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7: 728-35.
3. Kleiner DE, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993; 5: 891-7.
4. Murphy G, Reynolds JJ. Extracellular matrix degradation. In: Royce PM, Steinmann B, eds. Connective Tissue and its Heritable Disorders. New York: Wiley-Liss, 1993: 287-316.
5. Murphy G, Willenbrock F, Ward R et al. Studies on the structure and function of the matrix metalloproteinases and their inhibitors. In: Bond JS, Barrett AJ, eds. Proteolysis and Protein Turnover. Colchester: Portland Press Ltd, 1994: 25-32.
6. Reynolds JJ, Hembry RM, Meikle MC. Connective tissue degradation in health and periodontal disease and the roles of matrix metalloproteinases and their natural inhibitors. Adv Dental Res 1994; 8: 312-9.
7. Willenbrock F, Murphy G. Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med 1994; 150: S165-70.
8. Stocker W, Grams F, Baumann U et al. The metzincins - topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Prot Sci 1995; 4: 823-40.
9. Freije JMP, Diez-Itza I, Balbin M et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766-73.
10. Henriet P, Rousseau GG, Eeckhout Y. Cloning and sequencing of mouse collagenase cDNA. Divergence of mouse and rat collagenases from the other mammalian collagenases. FEBS Lett 1992; 310: 175-8.
11. Basset P, Bellocq JP, Wolf C et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
12. Murphy GJP, Murphy G, Reynolds JJ. The origin of matrix metalloproteinases and their familial relationships. FEBS Lett 1991; 289: 4-7.
13. Busiek DF, Baragi V, Nehring LC etal. Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J Immunol 1995; 154: 6484-91.
14. Hembry RM, Bagga MR, Reynolds JJ et al. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995; 54: 25-32.
15. Matrisian LM. The matrix-degrading metalloproteinases. BioEssays 1992; 14: 455-63.
16. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268: 23824-9.
17. Sato H, Takino T, Okado Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
18. Okada A, Bellocq JP, Rouyer N et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc NatlAcad Sci USA 1995; 92: 2730-4.
19. Takino T, Sato H, Shinagawa A et al. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 1995; 270: 23013-20.
20. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur J Biochem 1995; 231: 602-8.
21. Atkinson SJ, Ward RV, Reynolds JJ et al. Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases. Biochem J 1992; 288: 605-11.
22. Murphy G, Atkinson S, Ward R et al. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992; 667: 1-12.
23. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267: 3581-1.
24. Sorsa T, Ingman T, Suomalainen K et al. Identification of proteases from periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast-type interstitial collagenases. Infection Immunity 1992; 60: 4491-5.
25. Ward RV, Atkinson SJ, Slocombe PM et al. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta 1991; 1079: 242-6.
26. Ward RV, Atkinson SJ, Reynolds JJ et al. Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts. Biochem J 1994; 304: 263-9.
27. Cao J, Sata H, Takino T et al. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro gelatinase A activation. J Biol Chem 1995; 270: 801-5.
28. Strongin AY, Collier I, Bannikov G et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J Biol Chem 1995; 270: 5331-8.
29. Atkinson SJ, Crabbe T, Cowell S et al. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem 1995; 270: 30479-85.
30. Docherty AJP, O'Connell J, Crabbe T et al. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. TIBTECH 1992; 10: 200-7.
31. O'Shea M, Willenbrock F, Williamson RA et al. Site-directed mutations that alter the inhibitor activity of the tissue inhibitor of metalloproteinases-1: importance of the N-terminal region between cysteine 3 and cysteine 13. Biochemistry 1992; 31: 10146-52.
32. Stetler-Stevenson WG, Brown PD, Onisto M et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265: 13933-8.
33. Shapiro SD, Kobayashi DK, Welgus HG. Identification of TIMP-2 in human alveolar macrophages. Regulation of biosynthesis is opposite to that of metalloproteinases and TIMP-1. J Biol Chem 1992; 267: 13890-4.
34. Pavloff N, Staskus PW, Kishnani NS et al. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem 1992; 267: 17321-6.
35. Apte SS, Mattei M-G, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 1994; 19: 86-90.
36. Apte SS, Hayashi K, Seldin MF et al. Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn 1994; 200: 177-97.
37. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitor activities define the distinct TIMP gene family. J Biol Chem 1995; 270: 14313-8.
38. Leco KJ, Khokha R, Pavloff N et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994; 269: 9352-60.
39. DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994; 30A: 2170-80.
40. Dhawan S, Wahl LM, Heredia A et al. Interferon-gamma inhibits HIV-induced invasiveness of monocytes. J Leukocyte Biol 1995; 58: 713-6.
41. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory disfunction in disease. Biol Chem Hoppe-Seyler 1995; 376: 345-55.
42. West-Mays JA, Strissel KJ, Sadow PM et al. Competence for collagenase gene expression by tissue fibroblasts requires activation of an interleukin 1α autocrine loop. Proc Natl Acad Sci USA 1995; 92: 6768-72.
43. Mann EA, Hibbs MS, Spiro JD et al. Cytokine regulation of gelatinase production by head and neck squamous cell carcinoma: the role of tumor necrosis factor-alpha. Ann Otol Rhinol Laryngol 1995; 104: 203-9.
44. Lacraz S, Nicod LP, Chicheportiche R et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304-10.
45. Edwards DR, Murphy G, Reynolds JJ et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899-904.
46. Brown CC, Hembry RM, Reynolds JJ. Immunolocalization of metalloproteinases and their inhibitor in the rabbit growth plate. J Bone Joint Surg 1989; 71A: 580-93.
47. Breckon JJW, Hembry RM, Reynolds JJ et al. Regional and temporal changes in the synthesis of matrix metalloproteinases and TIMP-1 during development of the rabbit mandibular condyle. J Anat 1994; 184: 99-110.
48. Brinckerhoff CE. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum 1991; 34: 1073-5.
49. Dean DD, Martel-Pelletier J, Pelletier J-P et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84: 678-85.
50. Martel-Pelletier J, McCollum R, Fujimoto N et al. Excess of metalloproteinases over tissue inhibitor of metalloproteinase may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994; 70: 807-15.
51. Alexander MB, Damoulis PD. The role of cytokines in the pathogenesis of periodontal disease. Curr Opin Periodontal 1994: 39-53.
52. Everts V, Delaisse J-M, Korper W et al. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 1992; 150: 221-31.
53. Delaisse J-M, Vaes G. Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In: Ritkin BR, Gay CV, eds. Biology and Physiology of the Osteoclast. Boca Raton, FL: CRC Press , 1992; 289-314.
54. Hill PA, Buttle DJ, Jones SJ et al. Inhibition of bone resorption by selective inactivators of cysteine proteinases. J Cell Biochem 1994; 56: 118-30.
55. Hill PA, Murphy G, Docherty AJP et al. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 1994; 107: 3055-64.
56. Delaisse JM, Eeckout Y, Neff L et al. (Pro) collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartment. J Cell Sci 1993; 106: 1071-82.
57. Hill PA, Docherty AJP, Bottomley KMK et al. Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J 1995; 308: 167-75.
58. Okada Y, Naka K, Kawamura K et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 1995; 72: 311-22.
59. Meikle MC, Heath JK Reynolds JJ. Advances in understanding cell interactions in tissue resorption. Relevance to the pathogenesis of periodontal diseases and a new hypothesis. J Oral Pathol 1986; 15: 239-50.
60. Heath JK, Atkinson SJ, Hembry RM et al. Bacterial antigens induce collagenase and prostaglandin E2 synthesis in human gingival fibroblasts through a primary effect on circulating mononuclear cells. Infection Immunity 1987; 55: 2148-54.
61. Meikle MC, Atkinson SJ, Ward RV et al. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodont Res 1989; 24: 207-13.
62. Overall CM, Wiebkin OW, Thonard JC. Demonstration of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva. J Periodont Res 1987; 22: 81-8.
63. Larivee J, Sodek J, Ferrier JM. Collagenase and collagenase inhibitor activities in crevicular fluid of patients receiving treatment for localized juvenile periodontitis. J Periodont Res 1986; 21: 702-15.
64. Villela B, Cogen RB, Bartolucci AA et al. Collagenolytic activity in crevicular fluid from patients with chronic adult periodontitis, localized juvenile periodontitis and gingivitis, and from healthy control subjects. J Periodont Res 1987; 22: 381-9.
65. Lee W, Aitken S, Sodek J et al. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis. J Periodont Res 1995; 30: 23-33.
66. Hayakawa H, Yamashita K, Ohwaki K et al. Collagenase activity and tissue inhibitor of metalloproteinase-1 (TIMP-1) content in human whole saliva from clinically healthy and periodontally diseased subjects. J Periodont Res 1994; 29: 305-8.
67. Suomalainen K, Sorsa T, Golub LM et al. Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential. Antimicrob Agents Chemother 1992; 36: 227-9.
68. Smith GN, Brandt KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycling results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996; 39: 235-14.
69. Makela M, Salo T, Uitto VJ et al. Matrix metalloproteinases (MMP-2 and MMP-9) of the oral cavity: cellular origin and relationship to periodontal status. J Dent Res 1994; 73: 1397-106.
70. Teronen O, Salo T, Konttinen YT et al. Identification and characterization of gelatinases/type IV collagenases in jaw cysts. J Oral Pathol Med 1995; 24: 78-84.
71. Woolley DE, Davies RM. Immunolocalization of collagenase in periodontal disease. J Periodont Res 1981; 16: 292-7.
72. Meikle MC, Hembry RM, Holley J et al. Immunolocalization of matrix metalloproteinases and TIMP-1 (tissue inhibitor of metalloproteinases) in human gingival tissues from periodontitis patients. J Periodont Res 1994; 29: 118-26.
73. Mergenhagen SE. Thymocyte activating factor(s) in human gingival fluids. J Dent Res 1984; 63: 461-4.
74. Meikle MC, McAlpine CG, Heath JK et al. Interleukin-1 production by peripheral blood mononuclear cells from patients with severe periodontitis. In: Lehner T, Cimasoni G, eds. The Borderland between Caries and Periodontal Disease III. Geneva: Editions Medecine et Hygiene, 1986; 283-90.
75. Meikle MC, McFarland CG, Newman HN et al. Cytokines and connective tissue degradation in chronic inflammatory periodontal disease. In: Newman HN, Williams DM eds. Inflammation and Immunology in Chronic Inflammatory Periodontal Disease. Northwood, London: Science Reviews Ltd, 1992; 87-106.
76. Nagase H, Barrett AJ, Woessner JF. Nomenclature and glossary of the matrix metalloproteinases. Matrix 1992; (Suppl 1): 421-4.